P arkinson Study Group (www.parkinson-study-group. org/), and the NHS registry (www.nhs.uk/Conditions/ Clinical-trials/Pages/clinical-trial.aspx). The key search terms included Parkinson, protection, neuroprotection, progression, and modifying, during a specified date range from 1 January 2012 to 31 December 2013. All studies identified are discussed below.
The treatments for Parkinson's disease that are discussed are drawn from evidence based medicine reviews sponsored by the Movement Disorders Society (MDS), 12 13 Cochrane systematic reviews, and American Academy of Neurology recommendations. The evidence based medicine reviews applied systematic criteria to es tablish r atings that were based on published data from randomised controlled trials (RCTs) (summarized in fig 2) . Further details have been reported. 12 Whereas this system is straightforward for newer drugs, for older ones, which were originally evaluated when clinical trial design was less refined, efficacy conclusions are often based on limited and extrapolated data.
STAT E O F T H E A RT R EV I E W

Neuroprotection
Trials of drugs such as rasagiline, pramipexole, and ropinirole have yet to provide robust evidence of benefit. [14] [15] [16] However, research into neuroprotection continues to grow, and many cellular targets are being investigated. Several different approaches are being used, such as the reduction of oxidative stress, alteration of apoptotic pathways, production of tropic factors, and modulation of cell signaling (see www.clinicaltrials.gov for fuller listings).
Glutathione
An increase in oxidative stress has been proposed as one mechanism that leads to the loss of nigrostriatal dopaminergic cells in Parkinson's disease. There has been considerable interest in glutathione and its role as an antioxidant. 17 18 The activity of glutathione peroxidase and catalase is reduced in the midbrain of people with Parkinson's disease, suggesting that antioxidant defense mechanisms are disrupted in patients affected by the d isease.
19-21
Ubiquitin-proteasome sysytem Cell death can be caused by α synuclein aggregation, dysfunction of the proteosomal and lysosomal system (not shown), and reduced mitochondrial activity. Gene mutations are associated with impairment of one or several of these mechanisms. In addition, secondary changes (not shown), such as excitotoxicity and inflammation, are likely to play a role in progressive neuronal degeneration. Abbreviations: α-Sp22=22 kilodalton glycosylated form of α-synuclein; PAELR=parkin associated endothelin receptor-like receptor; UbCH7/8, ubiquitin conjugating enzyme 7/8; UCHL1, ubiquitin carboxy terminal hydrolase L1. Reproduced, with permission, from Nature Medicine 2 In a current double blind RCT, people with Parkinson's disease are receiving escalating doses of a nicotine transdermal patch or placebo for 52 weeks (NCT01560754). The primary outcome is change in the total UPDRS score between baseline and 60 weeks.
Pioglitazone
Drugs used for other indications such as diabetes are being evaluated for disease modifying effects in Parkinson's disease. The neuroprotective effects of pioglitazone have been shown in mouse models of Parkinson's disease. 29 The proposed mechanism of action is through activation of the peroxisome proliferator activated receptor, induction of inducible nitric oxide synthase, and nitric oxide mediated toxicity. 29 30 In the lipopolysaccharide model of Parkinson's disease, pioglitazone reduces both microglial activation and oxidative stress, allowing mitochondrial function to be restored. 31 Because pioglitazone inhibits MAO-B, it is not clear whether its effects are truly neuroprotective or just a reflection of this inhibitory effect. 32 33 This is currently being assessed by a multicenter double blind RCT in people on a stable dose of an MAO-B inhibitor randomized to either pioglitazone or placebo for 44 weeks (NCT01280123). The primary outcome measure is change in the total UPDRS score between baseline and 44 weeks.
Granulocyte colony stimulating factor
Granulocyte colony stimulating factor is a glycoprotein that belongs to the group of lineage specific hematopoietic colony growth factors. 34 Although it is commonly used to treat leukopenia, 35 receptors are widely expressed in CNS neurons and rodent substantia nigra dopaminergic neurons. 36 37 In mouse models of Parkinson's disease, granulocyte colony stimulating factor has been shown to provide dose dependent long term neuroprotection, with improvement in motor function. 34 Oral glutathione supplements do not produce higher levels of intracellular glutathione centrally owing to the presence of the blood-brain barrier. [7] [8] [9] However, efforts have been made to restore or increase glutathione through other mechanisms. Currently, an intranasal form of glutathione is being evaluated for safety, tolerability, and dosing ranges in a phase I study (clinicaltrials.gov; NCT01398748). Another study on the same glutathione pathway aims to raise glutathione concentrations indirectly through dietary supplementation with N-acetylcysteine, a derivative of cysteine, which is a rate limiting amino acid in the production of glutathione (NCT01470027).
Bee venom, which is protective in animal models of Parkinson's disease, 22 23 is now being explored as a n europrotective agent in people with the disease. One proposed mechanism of action is venom induced blockage of specific channels on dopaminergic neurons, which leads to activation of a calcium dependent signaling pathway and prevention of apoptosis. 24 In a current double blind RCT, people are receiving monthly subcutaneous injections of bee venom or placebo for a year (NCT01341431). The primary outcome measure is change in the total Unified Parkinson's Disease Rating Scale (UPDRS) score between baseline and one year.
Epidemiological data have provided valuable clues about the risks of developing Parkinson's disease, and these data have suggested other novel neuroprotective treatments.
Nicotine
The incidence of Parkinson's disease is lower in tobacco users than in non-users. [25] [26] [27] Studies have suggested that nicotine alters calcium signaling, resulting in adaptations in immune responsiveness and tropic factors that may reduce or arrest the neuronal damage that occurs in the disease. 28 nucleus. 46 47 The safety and tolerability of bilateral deep brain stimulation of the subthalamic nucleus is currently being evaluated (NCT00282152) in a pilot study. This study may provide the data to justify a large trial in people with Parkinson's disease.
STAT E O F T H E A RT R EV I E W
Enrollment in neuroprotective trials remains a challenge, and it is difficult to determine whether a particular agent actually slows disease progression. There is a large placebo effect in Parkinson's disease, 48 and no current available biomarker can determine whether patients are improving symptomatically or whether disease progression is being affected. This remains a major hurdle in assessing neuroprotective agents and in trial design.
Symptomatic treatment of Parkinson's disease: motor symptoms
From the first consultation onwards the patient's level of disability should be clinically assessed using validated scales. This allows longitudinal tracking of impairment and disability. The UPDRS and its recent revision by the MDS (MDS-UPDRS) are internationally recognized clinical scales that can be used to objectively assess the motor features of Parkinson's disease. Worsening scores over time may provide insight into the potency of drug that should be chosen. A summary of the recommendations for initial treatment of Parkinson's disease is provided by the American Academy of Neurology evidence based practice parameter (box 1). 49 Mild potency drugs MAO-B inhibitors MAO-B inhibitors extend the duration of action of the patient's own dopamine by reducing its metabolic breakdown. Their benefit may be seen as early as one week after the start of treatment. 50 In the MDS evidence based medicine review, selegiline and rasagiline met the "efficacious" and "clinically useful" designation for symptomatic monotherapy (see fig 2 for the definitions of efficacy categories). 16 51-56 A systematic review found that MAO-B inhibitors improve the symptoms of Parkinson's disease and delay the need for levodopa by a few months (weighted mean difference for change in motor UPDRS score was 3.81 points less with MAO-B inhibitors compared with controls, 95% confidence interval 2.27 to 5.36). However, it concluded that they are "too weak" to have a major benefit and "do not seem to delay the progression of the condition." 57 An oral disintegrating form of selegiline is available, but owing to insufficient evidence about its efficacy for monotherapy in Parkinson's disease, it is not a well established treatment.
As well as the antiparkinsonian effects of selegiline through its dopaminergic effect, other pharmacologic properties of selegiline include the inhibition of uptake of catecholamines and the release of catecholamine by amphetamine metabolites. 58 Patients taking selegiline should be counseled about the presence of this amphetamine metabolite because random drug screening in the workplace may yield a positive result. 59 Rasagiline is devoid of amphetamine-like metabolites and is taken only once a day, but it is more costly. An Proposed mechanisms include an anti-apoptotic effect on neuronal cells, 36 with a reduction in systemic inflammatory reactions 38 and induction of neurogenesis. 36 39 In a current double blind RCT, people with Parkinson's disease are receiving six cycles of high dose or low dose granulocyte colony stimulating factor or placebo for five consecutive days every 60 days (NCT01227681). The primary outcome measure is change in the motor UPDRS score between baseline and two years.
GM608
This endogenous human embryonic stage neural re gulatory and signaling peptide is being evaluated in Parkinson's disease, amyotrophic lateral sclerosis, and stroke. A phase II pilot double blind placebo controlled trial (NCT01227681) is currently assessing intravenous GM608 as a neuroprotective agent in people with Parkinson's disease. The primary outcome measure is change in the total UPDRS score between baseline and 12 weeks.
Exercise
Vigorous exercise has a neuroprotective effect in animal models of Parkinson's disease. 40 41 Exercise induces the expression of brain neurotrophic factors, including brain derived neurotrophic factor and glial derived neurotrophic factor, 42 43 both of which are significantly reduced in the substantia nigra of people with Parkinson's disease. 44 Several human trials of different types of exercise are ongoing, including moderate or vigorous treadmill exercise (NCT01506479), brisk walking (NCT00784563), and use of a stationary virtual reality bike (NCT01562496). Some of these studies are actively recruiting participants (NCT01506479, NCT01562496).
Generally, physical exercise is recommended for people with Parkinson's disease, and a systematic review found that treadmill training is likely to improve gait hypokinesia. 45 However, the duration and amount of training, as well as the duration of benefit, remain to be established. 
Surgery
Levodopa or dopamine agonist
In patients who require treatment with a dopaminergic drug, either levodopa or a dopamine agonist can be used. The choice depends on the relative need to improve motor symptoms (levodopa best) or reduce motor complications (dopamine agonists best) in the individual patient (level A evidence). For patients in whom levodopa treatment is being started, either an immediate release or sustained release preparation may be considered (level B evidence).
Amantadine may provoke changes in sleep-wake cycles, causing insomnia at night as a negative effect, or less daytime sleepiness, as a positive effect. These behaviors are probably due to the release of stored catecholamines from intact dopaminergic terminals and inhibition of catecholamine reuptake processes at the pre-synaptic terminal. 71 The specific impact of amantadine on fatigue remains to be studied in detail. Because amantadine is poorly metabolized and excreted as an active product in the urine, patients with renal compromise (high concentrations of creatinine in the blood) need to be carefully monitored and may not be able to tolerate twice daily treatment. Excess levels of amantadine in the bloodstream may result in myoclonus, agitation, psychosis and hallucinations in 1-10% of patients. 72 Other adverse reactions include edema of the lower extremities and livedo reticularis. 70 Congestive heart failure and orthostatic hypotension can occur d uring chronic amantadine administration, 12 73 so clinical monitoring and caution are needed in elderly patients with Parkinson's disease.
Anticholinergic drugs
Anticholinergic drugs act on muscarinic acetylcholine receptors to alter G protein activity, which results in modulation of the imbalance between striatal dopamine and acetylcholine activity. Several agents have been studied, including bornaprine, orphenadrine, trihexyphenidyl, and benztropine. A systematic review has led to a classification of "likely efficacious" and "clinically useful" by the MDS task force. 12 65-70 Adverse effects of anticholinergic drugs Although case reports have shown some benefit of anticholinergic drugs on tremor, 74 the evidence is conflicting, 75 and the adverse effects of this class of drugs often outweigh the benefits. Owing to the peripheral antimuscarinic action of these drugs, they are contraindicated in narrow angle glaucoma because blindness has been reported. 76 In addition to the autonomic effects that are typical of anticholinergic drugs, 2-12% of patients report impaired cognitive function, which severely limits their use, 77 especially in elderly people. Patients using anticholinergics have developed impaired neuropsychiatric function, with a 5-10% decrease in verbal memory that can be mild or severe enough to be clinically diagnosed as a dementiatype state. 77 78 Even in patients who had not shown any central nervous system side effects while on treatment, mental functions have improved after withdrawal of these drugs. 79 The use of anticholinergics is contraindicated in people with dementia.
Patients taking long term anticholinergics need to be weaned off treatment slowly, and abrupt withdrawal often leads to a rebound effect, with marked deterioration of parkinsonism and agitation. [80] [81] [82] Additional anticholinergic side effects, including tachycardia, constipation, urinary retention, and blurred vision should also be considered because they may lead to serious morbidity. 83 Not enough evidence is available to determine the frequency of these effects. economic analysis by the committee to evaluate drugs (part of the Canadian Expert Drug Advisory Committee) concluded that "it is unknown whether rasagiline offers any clinical advantage over selegiline." On the basis of cost analysis, rasagiline is therefore reserved for patients who have not responded to formulary alt ernatives. 60 
Adverse effects of MAO-B inhibitors
People with Parkinson's disease have a twofold to threefold increased incidence of melanoma compared with controls, although no clear association with dopaminergic drugs has been identified. 61 Patients should therefore have regular dermatological assessment regardless of the type of drug they take.
The concomitant use of antidepressants and MAO-B inhibitors has raised concerns about the theoretical risk of serotonin syndrome. However, no cases of serotonin syndrome were reported by a randomised trial of patients taking rasagiline and various antidepressants (amitriptyline hydrochloride, paroxetine, sertraline hydrochloride, fluvoxamine maleate, and trazodone hydrochloride), 62 or by a similar trial. 63 Careful monitoring of patients on combined treatment with MAO-B inhibitors and antidepressants is clinically prudent, and patients should be informed of typical symptoms of serotonin syndrome, such as rapid heart rate, hypertension, fever, myoclonus, and agitation. These are characterized by severe hypertensive crisis and are only a theoretical risk when MAO-B inhibitors are taken within the prescribed dosage range in patients with normal metabolic function.
When MAO-B inhibitors are given at high doses (s elegiline >10 mg or rasagiline >1 mg), they are nonselective and may also inhibit MAO-A. In this case, inhibition of MAO-A along with use of an antidepressant or tyramine containing foods (such as aged cheeses or cured meats) can trigger this tyramine reaction. Two randomised trials found no cases of tyramine reaction when patients were treated with the recommended doses of MAO-B inhibitors. 62 63 Amantadine Many of the clinical trials that have been used to establish the efficacy of amantadine were performed in the 1970s. 51 Level I studies assessing its use as mono therapy in P arkinson's disease have led to a classification of "likely efficacious" and "possibly useful." 12 
64-70
Impulse control disorders may respond to reducing or stopping the dopamine agonist, and no specific dopamine agonist seems to carry a higher risk than another. 96 This class of drug should be used with caution in people with pre-existing obsessive or compulsive tendencies, and it is important to monitor the emergence of impulse control disorders with specific questioning before and throughout therapy.
Dopamine agonists can induce daytime sleepiness and patients can fall asleep even while driving, eating, or talking, so patients should be counseled about driving safety. Hallucinations, usually visual, but sometimes involving other sensory modalities, can occur even in patients with early Parkinson's disease who are treated with these drugs. It is likely that impaired baseline cognition and older age increase the risk of hallucinations in people taking these drugs. 97 A systematic review and meta-analysis confirmed that motor fluctuations and dyskinesia are decreased with dopamine agonists compared with levodopa. However, it found an increase in side effects with dopamine agonists, including edema (odds ratio 3. 
Practical considerations when choosing a moderate potency agent
The non-ergot dopamine agonists are generally preferred to the ergot dopamine agonists, as discussed above. The main difference between the non-ergot dopamine agonists is their therapeutic window. Pramipexole is typically used at 0.5-1.5 mg three times a day, whereas ropinirole can be given at doses as low as 0.25 mg three times a day and up to 8 mg three times a day. The extended release formulations follow similar dosage guidelines as their immediate release counterparts, and, when adherence is a problem, these long acting formulations may be preferred by the clinician and patient.
Rotigotine is a transdermal dopamine agonist that has a usual therapeutic dosage range of 4-8 mg per 24 hours, and because it is given transdermally, patients do not have to worry about food or drug interactions within the gastrointestinal system.
No strong evidence favors the long acting (once daily) agonists over short acting ones in terms of efficacy, and nor is there evidence to favor one agonist over another. Patient and physician preference, cost, and convenience will guide the decision and choice. If a patient has adverse effects from a particular agonist an alternative agent can be tried within the class, but most side effects are class effects so may occur with any drug. As a result, the choice of one agonist over another is often based on patient preference, the physician's clinical experience with the agents, and insurance plans that cover one drug and not others.
High potency drugs: levodopa formulations
Levodopa augments striatal dopaminergic transmission by being converted directly into dopamine, resulting in marked clinical improvement. 99 100 Levodopa is typically
Practical considerations when choosing a mild potency agent Given the degree of potential cognitive side effects of anticholinergics and the evidence base, we generally avoid their use. If a patient has severe refractory tremor that is disabling, anticholinergics may help somewhat, but often at the expense of cognitive function. In choosing between the MAO-B inhibitors and amantadine, if tremor and fatigue are the main problems in a young person, we often favor amantadine. However, if the patient is elderly or has impaired renal function, the MAO-B inhibitors are preferable. When cost is a consideration and there is no concern about positive urine tests for amphetamine in the workplace, selegiline may be preferred over rasagiline. However, for the busy professional who does not want to take drugs twice a day, rasagiline's once daily administration is a strong advantage.
Moderate potency drugs: dopamine agonists
Mild potency drugs are not helpful in some people with early Parkinson's disease and some patients initially present with serious impairment. In these cases, clinicians may decide that a moderate potency option is needed. Dopamine agonists, which directly stimulate dopamine receptor sites, are the next logical choice. Available agents include bromocriptine, cabergoline, piribedil, pramipexole, ropinirole, and rotigotine. Dopamine agonists exist as ergot and non-ergot derivatives (box 2). Ergot derivatives are not commonly used owing to reports of pleuropulmonary and retroperitoneal fibrosis, as well as fibrotic valvular heart disease. [84] [85] [86] [87] [88] The MDS evidence based medicine reviews also examined the evidence for use of non-ergot dopamine agonists, 51 and it found that "efficacious" and "clinically useful" choices include piribedil, 89 pramipexole, 90 pramipexole extended release, 91 ropinirole, 92 93 and rotigotine. 93 Piribedil is not available for clinical use in the US or UK. Ropinirole prolonged release has also been used as monotherapy, but it has been classified as "likely efficacious" and "possibly useful" in the clinical setting. 94 Because the safety profile of the non-ergot dopamine agonists is superior to that of the ergot derivatives in terms of fibrotic complications (on the basis of case reports), the non-ergot dopamine agonists are the preferred choice.
Adverse effects
There is no strong evidence to favor one non-ergot agonist over another, and most side effects seen with one agent are also reported with the others. Adverse effects of dopamine agonists include fatigue (5-10%), nausea (15-22%), constipation (6-10%), and edema of the lower extremities (reported in 10-40%). [90] [91] [92] Two potentially severe side effects include the appearance of impulse control disorders or sleep attacks (sudden onset of sleep). Patients with impulse control disorders have a preoccupation with gambling, sexual activity, or other obsessions that can become serious and cause social problems. Impulse control disorders have been reported to occur in 5.6-13.8% of patients taking dopamine agonists, 95 and they seem to be more common in men and people with a history of gambling or risk taking behaviors. 95 may have less predictable improvement in their symptoms and less consistency from one dose to the next when using controlled release formulation. If patients have difficulty with mobility at night-time, the controlled release formulation is useful because the peak concentration is lower so there is less sleep disturbance. In addition, the longer duration of action provides more sustained antiparkinsonian benefits through the night.
Levodopa remains the gold standard treatment for Parkinson's disease and the most efficacious treatment. However, some clinicians favor starting the drug immediately, whereas others advise delaying its use. When levodopa was first introduced, reports of the occurrence of levodopa induced dyskinesia were as high as 58% after six months and 75% at one year. 108 One explanation might have been that patients with early levodopa induced dyskinesia had longer disease duration and fewer striatal dopaminergic terminals, resulting in earlier levodopa induced dyskinesia. 109 However, an alternative explanation may be that these patients were treated with higher doses of levodopa, which accelerated the development of levodopa induced dyskinesia. 110 Certainly as levodopa has been used more judiciously over the years the incidence of dyskinesia has decreased. 111 A study published in 2013 showed that the risk of developing dyskinesia and motor fluctuations increased in a levodopa dose dependent manner. 112 In summary, a levodopa sparing strategy should be considered, especially in people with early Parkinson's disease. Most patients will eventually require levadopa, but the decision to start should be discussed with patients after careful consideration of their age, disability, treatment goals, and potential for late complications of dyskinesia and hallucinations.
Additional considerations when starting treatment for motor symptoms
The urgency with which the patient requires symptomatic improvement will guide the choice of agent. If the patient is working and job security is imminently threatened, the mild potency drugs such as the MAO-B inhibitors or even the moderate potency agents (dopamine agonists) may take several weeks to have their full effect and may not be the most appropriate choice. In such cases, levodopa may be chosen because of its reliable rapid onset and high potency effects. By contrast, if the patient is retired and has mild disability the MAO-B inhibitors may be a reasonable first step. In more elderly patients, depending on their level of disability, levodopa may be considered as first line therapy because it is the most effective and potent drug and can have a major impact on quality of life, especially in protecting against falls and fractures. 113 Comorbidities should be considered when selecting the appropriate treatment. Non-motor symptoms such as orthostatic hypotension, fatigue, lower extremity edema, and cognitive problems may be present, either from Parkinson's disease or from another cause. Dopamine agonists may worsen cognition, provoke fatigue and sleepiness, and promote lower extremity edema.
Similarly, anticholinergic drugs can have cognitive side effects and worsen autonomic dysfunction. Orthostatic hypotension may be worsened by dopamine agonists given with a peripheral L-aromatic amino acid decarboxylase (L-AAAD) inhibitor, commonly carbidopa or benserazide. The addition of a peripheral L-AAAD inhibitor limits the peripheral breakdown of levodopa, permitting a roughly fourfold increase in the amount of levodopa that crosses the blood-brain barrier. 101 102 The MDS evidence based medicine review found that two levodopa formulations-the standard formulation and the controlled release one-were "efficacious" and "clinically useful." 51 Newer formulations of levodopa include a rapid onset oral one and a duodenal infusion. There is insufficient evidence about their use as symptomatic monotherapy and they are "investigational" in terms of efficacy and clinical use. 37 It is important to note that although levodopa is rated as "efficacious" and "clinically useful," no level I placebo controlled trials have established the efficacy of levodopa (standard or controlled release formulation) for the symptomatic control of Parkinson's disease. This is because standard levodopa came into existence at a time when study design was not standardized and firmly established, so strictly speaking the evidence base is weak. However, levodopa has been used for decades, and the effect size of levodopa in Parkinson's disease is large and consistent enough that it is considered the gold standard treatment. In fact, it has been the standard comparator agent in many trials. Its efficacy has been proved in large clinical studies such as the ELL-DOPA trial, which showed a clinically significant benefit of levodopa versus placebo on UPDRS scores over 40 weeks. The mean difference between the UPDRS score at baseline and at 42 weeks was 7.8 units in the placebo group, 1.9 units in those groups receiving 150 mg and 300 mg levodopa daily, and −1.4 in those receiving 600 mg daily (P<0.001), including two weeks after the drug was discontinued. 103 
Adverse effects
Treatment with levodopa is associated with several dopaminergic side effects including nausea, vomiting, and hypotension. 104 Hallucinations may occur, although they are less common with levodopa than with dopamine agonists. 104 Other side effects, including edema (14%), sedation (20%), and dizziness (10%), are less common with levodopa than with dopamine agonists. 51 The incidence of levodopa induced dyskinesias in prospective randomized long term trials varies between less than 20% to more than 50% at five years. 104 105 To delay dyskinesias, alternative drugs such as dopamine agonists, which are associated with a lower risk of dyskinesia and motor fluctuations than levodopa, should be considered first. 106 
Practical considerations when using high potency drugs
The standard formulation of levodopa works most effectively for day to day use in early Parkinson's disease. The controlled release formulation delays the peak levodopa concentration beyond that of the immediate release preparation by 45-90 minutes and has decreased bioavailability, resulting in a 30% reduction in a dose equivalence. 107 Because of this, patients with early Parkinson's disease with those taking placebo, 121 resulting in melatonin being classified as "possibly useful" for insomnia in such patients. No high quality RCTs about sleep attacks have been identified. Three RCTs have assessed the efficacy of the wake promoting agent, modafinil, to treat excessive daytime sleepiness in Parkinson's disease but had conflicting results, so no definite conclusions can be drawn.
Other non-motor symptoms No high quality RCTs have assessed REM behavior disorder and anxiety in early Parkinson's disease. Additional non-motor symptoms including autonomic dysfunction, pathologic punding, dementia, psychosis, and drug related impulse dyscontrol are not particularly prominent in early Parkinson's disease, but trials investigating these problems are covered in the full report of the MDS evidence based medicine reviews. Although early fetal transplant studies were unsuccessful, 122 123 one case report study reported the long term clinical outcome of human fetal cell transplantation in two people with Parkinson's disease. 124 These patients received intrastriatal grafts of human fetal ventral mesencephalic tissue and had clinical assessments at 15 and 18 years post-transplant. Although both patients had impressive sustained motor benefit, they are just two cases from a total of 18 patients who received the grafts. The authors report that the outcomes in all cases were favorable overall, but that adverse effects such as graft induced dyskinesia also occurred. These results are sufficiently encouraging to foster further studies as new stem cell based dopaminergic cell therapies and techniques are developed.
Gene therapies are also available and studies thus far have shown them to be safe but further trials are needed. 125 No studies have focused on gene therapy in early disease. For instance, ProSavin, a lentiviral vector based gene therapy, has been evaluated in an open label trial with the goal of restoring local and continuous dopamine production in people with Parkinson's disease. 125 However, the efficacy results are within the placebo range reported in other clinical trials of surgical interventions in Parkinson's disease, 126 127 so the long term benefit remains to be evaluated in randomized double blind trials.
Repositioning of existing drugs is another way to accelerate the acquisition of new therapeutics for Parkinson's disease. Given the large number of potential agents, efforts to streamline this process are being made. For instance, an international committee of experts has been assembled to systematically examine drugs that are currently used, or being developed, in other therapeutic areas, and prioritize those that are most suited to move into pilot clinical trials of Parkinson's disease. 128 Such and levodopa preparations. To avoid or reduce the risk of aggravating comorbidities, these effects are best considered before choosing a treatment.
Symptomatic treatment of Parkinson's disease: non-motor symptoms
The non-motor symptoms of Parkinson's disease can also be evident early on in the disease process. The most common of these are depression, fatigue, and disorders of sleep and wakefulness. These non-motor symptoms can have a greater negative impact on quality of life than motor sy mptoms, particularly in early Parkinson's di sease. 114 
Depression
Depression subtypes in Parkinson's disease remain to be delineated and validated. The two drugs that have been shown to be "efficacious" and "clinically useful" 51 for depression in Parkinson's disease are pramipexole [115] [116] [117] and venlafaxine. 118 Limited evidence exists for the use of tricyclic antidepressants including nortriptyline and desipramine, so these have been classified as "likely efficacious" and "possibly useful" by the MDS task force. 51 "Insufficient evidence" is available to draw conclusions about selective serotonin reuptake inhibitors, MAO-B inhibitors, and newer agents such as atomoxetine and nefazodone. Although alternative treatments such as omega-3 fatty acids and non-pharmacologic interventions including repetitive transcranial magnetic stimulation and electroconvulsive therapy have been considered, there is "insufficient evidence" to support their use. 51 Interestingly, cognitive behavioral therapy has been shown to be "likely efficacious" for the treatment of depression, 119 but further studies are needed to strengthen these results according to the most recent MDS evidence based medicine review. 120 Fatigue Two drugs have been considered for the treatment of fatigue in Parkinson's disease-methylphenidate and modafinil. Studies on fatigue have not exceeded eight weeks in duration, so conclusions can be made only about the short term effects. On the basis of the limited data, there is "insufficient evidence" for the efficacy of methylphenidate and modafinil for the treatment of fatigue in Parkinson's disease. As such, these drugs remain categorized as "investigational" in terms of established efficacy and clinical use.
Sleep disturbance
Although insomnia and fragmented sleep may be prominent symptoms in early Parkinson's disease, no studies have assessed treatment for longer than 10 weeks. Therefore, conclusions can be made regarding the short term treatment of insomnia only. Drugs that have been evaluated include pergolide, carbidopa-levodopa, eszopiclone, and melatonin (3 mg, 5 mg, and 50 mg). For all of these drugs, there is "insufficient evidence" regarding efficacy. Except for melatonin, these agents are considered "investigational use" in clinical practice. 51 In a small RCT, patients with Parkinson's disease taking melatonin 3 mg daily had subjective improved quality of sleep (P=0.03) compared These two strategies may be mutually exclusive because many neuroprotective trials enroll patients who are not receiving another treatment to avoid the bias of pharmacologic therapy. The decision to enroll in neuroprotective trials is an individual one and may be influenced by age, job security, current state of disease, and comorbid illnesses. Furthermore, many patients may not have access to research opportunities owing to lack of proximity to an academic center.
As such, in many instances the decision revolves around when to start symptomatic treatment and which symptom(s) should be targeted. The benefits and adverse effects of the treatments discussed need to be matched with the patient's level of disability and treatment goals. As the patient advances through the different stages of the disease, the treatment endpoints may change, and an alternative agent or supplementation with additional drugs may be needed.
Gene and cell based therapies are currently considered particularly invasive and are reserved for moderate and advanced cases of Parkinson's disease, but even patients with early disease will have questions and interest in these strategies. In the future, once the safety, tolerability, and efficacy of these potential treatments are established, clinicians will be able to intervene early in the disease to provide both neuroprotective and symptomatic tre atment.
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committee based approaches may help to identify the most promising drug candidates in a timely manner.
Existing drugs for Parkinson's disease can also be reformulated to provide novel methods of administration, improve tolerability, and minimize adverse effects. New drug delivery systems are being evaluated for levodopa, dopamine agonists, and other agents. 129 Non-dopaminergic drugs that target receptors on different parts of the basal ganglia network are in development. Several classes of such drug are in clinical trials including adenosine A2A receptor antagonists, glutamatergic antagonists, α adrenergic antagonists, and serotonergic agonists. 130 These treatments will need to be compared with existing treatments to show superiority or, at the minimum, non-inferiority.
As new neuroprotective treatments are produced and currently available drugs are optimized, this resulting larger selection of therapies might enable clinicians to tailor treatments to the individual patient. Furthermore, newer less invasive forms of functional neurosurgery such as focused ultrasound may be attractive even in patients with early Parkinson's disease, but further studies are needed to evaluate such therapies.
Guidelines
Clinical practice guidelines can be useful for making decisions on the diagnosis and treatment of Parkinson's disease. In the US, the American Academy of Neurology has published guidelines on the treatment of Parkinson's disease (www.aan.com/guidelines/).
The MDS-European Section (MDS-ES) and the European Federation of Neurological Societies (EFNS) have collaborated to provide recommendations applicable in Europe for the management of Parkinson's disease. 131 In the UK, the National Institute for Health and Care Excellence has guidelines for physicians, nurses, and other healthcare professionals on Parkinson's disease (www.nice.org.uk/CG035), as has the Scottish Intercollegiate Guidelines Network (www.sign.ac.uk/guidelines/ fulltext/113/index.html).
Conclusion
Parkinson's disease is a complex disorder with many potential treatment options, especially early in the disease. In the initial consultation, as patients deal with their new diagnosis, they require education about the two different treatment paths-neuroprotection for preservation of cells versus symptom control for augmentation of neurotransmitter function, primarily using dopamine.
FUTURE RESEARCH QUESTIONS
What is the initial biochemical reaction or set of reactions that starts the cascade of neurodegeneration in Parkinson's disease? Should surgical intervention be considered in early disease? What are the genetic, environmental, or clinical factors that produce different levels of disease decline? Once the technical problems of effective gene delivery to the substantia nigra are overcome, will gene delivery provide benefits in Parkinson's disease?
